Universität zu Köln

Leuchte, Katharina, Schlaak, Max, Stadler, Rudolf, Theurich, Sebastian ORCID: 0000-0001-5706-8258 and von Bergwelt-Baildon, Michael (2017). Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation. Oncol. Res. Treat., 40 (5). S. 262 - 270. BASEL: KARGER. ISSN 2296-5262

Full text not available from this repository.

Abstract

Cutaneous T-cell lymphomas (CTCL) are a rare and biologically heterogeneous malignant entity comprising mycosis fungoides and Sezary syndrome as the most common subtypes. The current treatment outcome is characterized by high rates of relapse, but survival is usually not significantly shortened in low-stage disease. This is different in tumor-stage disease or aggressive CTCL subtypes where survival is significantly reduced. Recent advances have been made on several levels of tumor biology: Whole genome sequencing has resulted in novel strategies of NF-kappa B or JAK inhibition, ongoing translational research has revealed new targets like CD30 or CCR4, and, finally, research focusing on impaired immunosurveillance has gained more importance. Based on the growing knowledge about the functional roles of the tumor microenvironment and non-malignant infiltrating cells, current research aims to develop novel CTCL treatment strategies. This review focuses on the mounting evidence for efficiently targeting tumor-infiltrating immune cells and thereby modulating the tumor microenvironment and restoring immunosurveillance. (C) 2017 S. Karger GmbH, Freiburg

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Leuchte, Katharina UNSPECIFIED UNSPECIFIED UNSPECIFIED Schlaak, Max UNSPECIFIED UNSPECIFIED UNSPECIFIED Stadler, Rudolf UNSPECIFIED UNSPECIFIED UNSPECIFIED Theurich, Sebastian UNSPECIFIED orcid.org/0000-0001-5706-8258 UNSPECIFIED von Bergwelt-Baildon, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-246426
DOI:	10.1159/000472257
Journal or Publication Title:	Oncol. Res. Treat.
Volume:	40
Number:	5
Page Range:	S. 262 - 270
Date:	2017
Publisher:	KARGER
Place of Publication:	BASEL
ISSN:	2296-5262
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PROTEASOME INHIBITOR BORTEZOMIB; FUNCTION IN-VITRO; PHASE-II TRIAL; MYCOSIS-FUNGOIDES; SEZARY-SYNDROME; BRENTUXIMAB VEDOTIN; MONOCLONAL-ANTIBODY; B-CELLS; EXPRESSION; ALEMTUZUMAB Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24642